Geode Capital Management
TRVI icon

Geode Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Geode Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.2M Buy
2,778,231
+365,346
+15% +$4.09M ﹤0.01% 1721
2025
Q4 		$30.2M Buy
2,412,885
+191,959
+9% +$2.22M ﹤0.01% 1784
2025
Q3 		$20.3M Buy
2,220,926
+434,081
+24% +$3.25M ﹤0.01% 1993
2025
Q2 		$9.78M Buy
1,786,845
+171,980
+11% +$1.07M ﹤0.01% 2383
2025
Q1 		$10.2M Buy
1,614,865
+315,543
+24% +$1.51M ﹤0.01% 2285
2024
Q4 		$5.35M Buy
1,299,322
+35,156
+3% +$113K ﹤0.01% 2717
2024
Q3 		$4.22M Buy
1,264,166
+117,418
+10% +$349K ﹤0.01% 2848
2024
Q2 		$3.42M Buy
1,146,748
+248,783
+28% +$691K ﹤0.01% 2925
2024
Q1 		$3.1M Buy
897,965
+48,084
+6% +$107K ﹤0.01% 2935
2023
Q4 		$1.14M Buy
849,881
+62,241
+8% +$94.2K ﹤0.01% 3306
2023
Q3 		$1.72M Buy
787,640
+8,819
+1% +$19.9K ﹤0.01% 3123
2023
Q2 		$1.86M Buy
778,821
+530,528
+214% +$1.34M ﹤0.01% 3134
2023
Q1 		$459K Buy
248,293
+36,746
+17% +$83.1K ﹤0.01% 3673
2022
Q4 		$408K Buy
211,547
+11,326
+6% +$22.3K ﹤0.01% 3764
2022
Q3 		$308K Buy
200,221
+5,075
+3% +$16.6K ﹤0.01% 3972
2022
Q2 		$548K Buy
195,146
+122,402
+168% +$301K ﹤0.01% 3711
2022
Q1 		$160K Buy
72,744
+23,667
+48% +$24.5K ﹤0.01% 4478
2021
Q4 		$38K Hold
49,077
– – ﹤0.01% 4896
2021
Q3 		$67K Hold
49,077
– – ﹤0.01% 4749
2021
Q2 		$110K Hold
49,077
– – ﹤0.01% 4536
2021
Q1 		$133K Hold
49,077
– – ﹤0.01% 4233
2020
Q4 		$118K Hold
49,077
– – ﹤0.01% 4024
2020
Q3 		$197K Buy
49,077
+7,164
+17% +$33.7K ﹤0.01% 3728
2020
Q2 		$275K Hold
41,913
– – ﹤0.01% 3570
2020
Q1 		$137K Buy
41,913
+431
+1% +$1.96K ﹤0.01% 3660
2019
Q4 		$155K Hold
41,482
– – ﹤0.01% 3882
2019
Q3 		$186K Hold
41,482
– – ﹤0.01% 3798
2019
Q2 		$311K Buy
+41,482
New +$357K ﹤0.01% 3637

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Geode Capital Management's TRVI Position: Q1 2026 in Review

Geode Capital Management increased its Trevi Therapeutics (TRVI) stake by 15% in Q1 2026, buying an estimated $4.09M and bringing the position to 2,778,231 shares worth $33.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1721.

Geode Capital Management first reported a position in TRVI in Q2 2019 and has held it in 28 quarters since. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Geode Capital Management held 2,778,231 shares of Trevi Therapeutics worth $33.2M as of Q1 2026.
  • Geode Capital Management bought 365,346 Trevi Therapeutics shares in Q1 2026, an estimated $4.09M.
  • Trevi Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1721 holding.
  • Geode Capital Management first reported a position in Trevi Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.